{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"semaglutide","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/semaglutide/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/semaglutide/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/semaglutide/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"semaglutide","title":"semaglutide","register":"standard","tags":[],"updated_at":"2026-07-17T02:41:42.872Z","body_excerpt":"## Overview\nEvidence is being populated by Grok web search.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","summary":"71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","summary":"Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","summary":"RCT evaluating semaglutide in T1D + obesity.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","summary":"2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","summary":"New Phase III trial registration for semaglutide (Jul 2025).","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","summary":"Discusses semaglutide benefits in CV and kidney outcomes.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","summary":"Real-world study on semaglutide weight loss, published Jun 2026.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","summary":"Study on weight loss efficacy of semaglutide 2.4 mg.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","summary":"Exploratory analysis from SELECT trial on hospitalizations.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"e143dd5e102d49671d4f288083c99778f9b4d7464c7e2535d68ad0aa9288f32a"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40934115/","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","quote":"Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity. (Funded by Novo Nordisk; OASIS 4 ClinicalTrials.gov number, NCT05564117.).","summary":"71-week RCT: -13.6% weight loss with 25 mg oral sema vs -2.2% placebo; more GI AEs.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"bb8f7bdc39d23ad49888cd19a335fda1e7783ea55f1f59f15ef2164ec8f15a12"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40961952/","title":"Once-weekly semaglutide 7·2 mg in adults with obesity","quote":"Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile.","summary":"Phase 3 trial of higher-dose semaglutide 7.2 mg for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"a26d95c594e153fa6cee12b32dce33708be46115da745ec03635be9106edef22"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40550013/","title":"Semaglutide in Adults with Type 1 Diabetes and Obesity","quote":"Once-weekly semaglutide is approved for the management of type 2 diabetes and obesity. The efficacy and safety of semaglutide in adults with type 1 diabetes and obesity are unknown.","summary":"RCT evaluating semaglutide in T1D + obesity.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"b8aa6e33c7d6a9587c779a0a3bcbb6fc45fb40ff84f9c8bc40dbd815a581f4fa"},{"id":"s4","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40620322/","title":"The expanding role of semaglutide: beyond glycemic control","quote":"This review outlines semaglutide's diverse mechanisms of action, including its roles in glucose homeostasis, weight reduction, and cardiovascular protection.","summary":"2025 review on semaglutide's expanding indications (NAFLD, HF, PCOS, etc.).","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"5ba89ac1dc2887caeb306538931575a3b58a6acb218e5bc5e91b92d905b63c87"},{"id":"s5","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07046273","title":"Phase III Clinical Study on the Efficacy and Safety of Semaglutide","quote":"A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...","summary":"New Phase III trial registration for semaglutide (Jul 2025).","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"43aabd42096e8232e61d29385dfa4dc0c096e20ac6d4b33e4fddc8ef1f1f0506"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40458885/","title":"Semaglutide in cardiovascular and kidney disease","quote":"Semaglutide enhances glycemic control , reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.","summary":"Discusses semaglutide benefits in CV and kidney outcomes.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"ad426f57cb10fd757fd7f601889f824534ba04baa4b49ef0724a3c5de77c70a5"},{"id":"s7","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT07627074","title":"Weight Loss in Adults Using Semaglutide (Real-world Study)","quote":"The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at ...","summary":"Real-world study on semaglutide weight loss, published Jun 2026.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"cd0c8309e785256b92d5506a7127de739c27491051f69213c016d128c32e2c4d"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40732345/","title":"Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in ...","quote":"Conclusions: The observed difference in weight loss efficacy between the groups was clinically meaningful. While once-weekly semaglutide at 2.4 mg elicited ...","summary":"Study on weight loss efficacy of semaglutide 2.4 mg.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"d0fbb127adadc67f08440e7f603c74a9e05cfe7e71528c7eea1cd2bea37d6bfa"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41433034/","title":"Semaglutide and Hospitalizations in Patients With Obesity ...","quote":"Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, ...","summary":"Exploratory analysis from SELECT trial on hospitalizations.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"e143dd5e102d49671d4f288083c99778f9b4d7464c7e2535d68ad0aa9288f32a"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"semaglutide","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":0,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":0,"claims_total":0,"sources":9,"anecdotal":0,"scientific":9,"user_reports":0,"questions":0,"evidence_ingests":0}}